<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28371" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Renal Tubular Acidosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mustaqeem</surname>
            <given-names>Ruqqiya</given-names>
          </name>
          <aff>Foundation Un Medical College, Islamabad</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Arif</surname>
            <given-names>Ali</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ruqqiya Mustaqeem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ali Arif declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28371.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Kidneys play a pivotal role in maintaining the acid-base balance of body along with lungs, and they do so by reabsorbing filtered bicarbonate and removing excess hydrogen ions. Renal disorders due to the removal of HCO3 or acid handling in the presence of relatively preserved GFR are collectively referred to as renal tubular acidosis. It is a non-anion gap hyperchloremic metabolic acidosis. This activity reviews the causes, pathophysiology, and presentation of renal tubular acidosis and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the types of renal tubular acidosis.</p></list-item><list-item><p>Review the pathophysiology of renal tubular acidosis.</p></list-item><list-item><p>Summarize the treatment for renal tubular acidosis.</p></list-item><list-item><p>Describe interprofessional team strategies for improving care and outcomes in patients with renal tubular acidosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28371&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28371">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28371.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Kidneys play a pivotal role in maintaining the acid-base balance of body along with lungs, and they do so by reabsorbing filtered bicarbonate and removing excess hydrogen ions. Renal disorders due to the removal of HCO3 or acid handling in the presence of relatively preserved GFR are collectively referred to as renal tubular acidosis. It is a non-anion gap hyperchloremic metabolic acidosis.</p>
        <p>There are four subtypes of RTA. The three main subtypes of RTA correlate with three mechanisms that facilitate renal acid-base handling, i.e., proximal bicarbonate reabsorption mainly as a result of Na-H exchange (85% to 90%), distal hydrogen ion excretion-primarily a function of collecting tubules and generation of NH3, the principal urinary buffer&#x000a0;<xref ref-type="bibr" rid="article-28371.r1">[1]</xref>.</p>
        <p>The subtypes are&#x000a0;as follows:</p>
        <list list-type="order">
          <list-item>
            <p>Type 1: Distal RTA</p>
          </list-item>
          <list-item>
            <p>Type 2: Proximal RTA</p>
          </list-item>
          <list-item>
            <p>Type 3: Mixed RTA</p>
          </list-item>
          <list-item>
            <p>Type 4:Hyporeninemic hypoaldosteronism RTA</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28371.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>
<bold>Type 1 Distal</bold>
</p>
        <p>Autoimmune diseases are the&#x000a0;commonest cause in adults: Systemic lupus erythematosus (SLE), Sjogren syndrome, rheumatoid arthritis, systemic sclerosis, thyroiditis, hepatitis, primary biliary cirrhosis&#x000a0;<xref ref-type="bibr" rid="article-28371.r2">[2]</xref>.</p>
        <p><italic toggle="yes">Inherited, AD or AR:</italic> Genetic primary causes of distal RTA include mutations of genes that encode the chloride-bicarbonate exchanger (AE1) or subunits of the H-ATPase pump&#x000a0;respectively</p>
        <p><italic toggle="yes">Genetic associations:</italic> Marfan syndrome, Ehler Danlos syndrome, sickle cell disease, congenital obstruction of the urinary tract</p>
        <p><italic toggle="yes">Nephrocalcinosis:</italic>&#x000a0;Chronic hypercalcemia, medullary sponge kidney</p>
        <p>Tubulointerstitial diseases: chronic pyelonephritis, chronic interstitial nephritis, obstructive uropathy, renal transplant rejection</p>
        <p><italic toggle="yes">Hypergammaglobulinemic states:</italic> Monoclonal gammopathy, multiple myeloma, amyloidosis, cryoglobulinemia, chronic liver disease</p>
        <p><italic toggle="yes">Drugs:</italic> Lithium, amphotericin B, NSAIDs, lead, antivirals</p>
        <p><italic toggle="yes">Miscellaneous:</italic> Idiopathic, familial hypercalciuria, glue sniffing (toluene inhalation in recreational drug abuse)&#x000a0;<xref ref-type="bibr" rid="article-28371.r3">[3]</xref></p>
        <p>
<bold>Type 2 Proximal</bold>
</p>
        <p><italic toggle="yes">Hypergammaglobulinemic states:</italic>&#x000a0;Most common cause in adults-monoclonal gammopathy(light chain), multiple myeloma, amyloidosis</p>
        <p><italic toggle="yes">Inherited:</italic> AD or AR putative mutations in Na-H antiporter in apical membrane and Na-HCO3 cotransporter in the basolateral membrane of proximal tubular cells&#x000a0;respectively</p>
        <p><italic toggle="yes">Drugs:</italic> Lead or other heavy metals, carbonic anhydrase inhibitors (e.g., acetazolamide, topiramate)&#x000a0;<xref ref-type="bibr" rid="article-28371.r4">[4]</xref>, out of date tetracyclines, aminoglycosides, valproate, mercury, tenofovir, and ifosfamide (nephrotoxic)</p>
        <p><italic toggle="yes">Autoimmune:</italic> Sjogren syndrome, systemic lupus erythematosus (SLE)</p>
        <p><italic toggle="yes">Miscellaneous:</italic> Interstitial nephritis, Fanconi syndrome, vitamin D deficiency, secondary hyperparathyroidism, chronic hepatitis, idiopathic</p>
        <p>
<bold>Type 3 Mixed</bold>
</p>
        <p><italic toggle="yes">Inherited:</italic> Mutations in carbonic anhydrase II.</p>
        <p>
<bold>Type 4 Hyperkalemic RTA</bold>
</p>
        <p><italic toggle="yes">Hyporeninemic hypoaldosteronism:</italic> most common cause in adults is diabetic nephropathy-destruction of JG apparatus due to vascular hyalinosis&#x000a0;<xref ref-type="bibr" rid="article-28371.r5">[5]</xref></p>
        <p><italic toggle="yes">Drugs:</italic> Potassium-sparing diuretics, beta blockers, NSAIDs, calcineurin inhibitors (cyclosporine, tacrolimus), ACEi, ARBs, renin inhibitors, heparin, TMP/SMX</p>
        <p><italic toggle="yes">Autoimmune:</italic> SLE</p>
        <p><italic toggle="yes">Genetic:</italic> Sickle cell disease, pseudohypoaldosteronism</p>
        <p><italic toggle="yes">Miscellaneous:</italic> Interstitial nephritis, chronic obstruction of the urinary tract, adrenal insensitivity to angiotensin II, renal insufficiency</p>
      </sec>
      <sec id="article-28371.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>RTA with its all major subtypes is an uncommon entity. The disease is undiagnosed in most of the&#x000a0;cases&#x000a0;and also in cases with incomplete RTA.&#x000a0;Inherited forms of RTA are much rarer than acquired forms. The most common Type in the United States and worldwide is type 4 hyperkalemic RTA, the main causes of which are diabetic nephropathy leading to hyporeninemic hypoaldosteronism and urinary tract obstruction. There&#x000a0;is over 20% incidence of developing RTA after renal transplant in the setting of rejection or immunosuppressive drugs.&#x000a0;</p>
        <p>Type 2 Proximal RTA is rarer than type 1 distal RTA and Fanconi syndrome is very rare as a primary disease. The diseases which are associated with Fanconi syndrome, for example, Wilson&#x000a0;disease, cystinosis, galactosemia, hereditary fructose intolerance and von Gierke&#x000a0;disease, are also rare. RTA associated with certain drugs such as antivirals for the treatment of HIV and viral hepatitis is increasing in incidence&#x000a0;<xref ref-type="bibr" rid="article-28371.r6">[6]</xref>.</p>
        <p>Type 3 Mixed RTA is vanishingly rare hereditary form of disease mostly affecting children from Arabic, North African, and Middle Eastern descent.</p>
      </sec>
      <sec id="article-28371.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>
<bold>Type 1 Distal RTA</bold>
</p>
        <p>Distal tubule is responsible for generating new bicarbonate under influence of aldosterone. Damage to alpha-intercalated cells of distal tubule causes no new generation of bicarbonate and thus no hydrogen ions. This raises the pH of urine due to an inability to excrete acid and generate acidic urine in the distal tubule, even in states of metabolic acidosis. It is associated with hypokalemia due to the failure of H/K ATPase.</p>
        <p>Other mechanisms include decreased functioning of H-ATPase, increased leak of protons from the tubule back into the lumen as seen in amphotericin B toxicity and reduced sodium reabsorption due to damage to alpha-intercalated cells of distal tubule which decreases the secretion of both protons and potassium. That is why, in cases of impaired sodium reabsorption, which most often occurs with obstructive uropathy or sickle cell disease, hyperkalemia may be observed.</p>
        <p>Incomplete distal RTA:&#x000a0;Patients with the incomplete form of distal RTA have a persistently high urine pH and hypocitraturia, as in the complete form, but can maintain net acid excretion and the plasma bicarbonate concentration in the normal range. The pathogenesis of this disorder is not well understood. These patients can develop hypercalciuria, hypocitraturia, and nephrolithiasis, and treatment with alkali therapy may ameliorate stone formation. Thus, incomplete distal RTA should be considered in any calcium stone formers with a urine pH persistently 5.5 or higher in the absence of infection.</p>
        <p>
<italic toggle="yes">
<bold>Genetic Causes</bold>
</italic>
</p>
        <p><italic toggle="yes">Autosomal dominant:</italic>&#x000a0;Mutations of the&#x000a0;<italic toggle="yes">SLC</italic>4A1 gene (chromosome 17q21-q22), which encodes the chloride-bicarbonate exchanger (AE1 or band 3), have been described in several families with distal RTA, causing mild acidosis.</p>
        <p><italic toggle="yes">Autosomal recessive with deafness:</italic> Patients with mutations in the gene <italic toggle="yes">ATP</italic>6V1B (chromosome 2p13), which is expressed in alpha-intercalated cells of distal tubule and cochlear encoding the B1 subunit of H-ATPase, have distal RTA and bilateral sensorineural deafness. Untreated patients develop severe metabolic acidosis with poor growth, rickets, and nephrocalcinosis during infancy and early childhood&#x000a0;<xref ref-type="bibr" rid="article-28371.r7">[7]</xref>.</p>
        <p><italic toggle="yes">Autosomal recessive without deafness:</italic>&#x000a0; Patients with mutations in the gene <italic toggle="yes">ATP</italic>6V0A4 (chromosome 7q33-q34), which encodes the a4 subunit of H-ATPase, develop distal RTA without early hearing loss. The severity of metabolic acidosis and its associated findings of failure to thrive, rickets, and nephrocalcinosis are similar to that seen in patients with mutations that affect the B1 subunit.</p>
        <p>Investigations have also shown an association of pathogenic alleles of SLC34A1 to both autosomal dominant and recessive forms of the renal stone disease&#x000a0;<xref ref-type="bibr" rid="article-28371.r8">[8]</xref>.</p>
        <p>
<bold>Type 2 Proximal</bold>
</p>
        <p>Normally 85% to 90% of bicarbonate is reabsorbed at proximal tubule, and only 10% reabsorbed at distal tubule. Due to a bicarbonate leak, impaired proximal HCO3 reabsorption in proximal tubule results in excess HCO3 in urine leading to metabolic acidosis. It is often associated with Fanconi syndrome and is rarer than type 1. Hypokalemia is common due to osmotic diuresis because of decreased HCO3 reabsorption causing increased flow rate to distal tubule and causing increased K excretion.</p>
        <p>Due to a reduced capacity to reclaim filtered bicarbonate, a patient with proximal RTA will be able to completely reclaim filtered bicarbonate if the plasma bicarbonate concentration is below the patient&#x02019;s reduced threshold for reclaiming bicarbonate, thus maintaining the normal or near normal urine pH. If the plasma bicarbonate is above this level, bicarbonate appears in the urine raising the pH of urine, as the filtered bicarbonate load will exceed the reduced absorptive capacity. This is why, in proximal RTA, the urine pH is variable and dependent upon whether the patient is being treated with alkali therapy.</p>
        <p>Proximal RTA in adults may also result from carbonic anhydrase inhibitors, which impair proximal bicarbonate reabsorption without affecting the reabsorption of other proximal tubule solutes. Nephrotoxic drugs such as tenofovir and ifosfamide can produce Fanconi syndrome.</p>
        <p>
<bold>
<italic toggle="yes">Genetic Causes&#x000a0;<xref ref-type="bibr" rid="article-28371.r9">[9]</xref></italic>
</bold>
</p>
        <p>Autosomal recessive: Rare mutations in the gene <italic toggle="yes">SLC</italic>4A4, which encodes the sodium bicarbonate cotransporter, are associated with isolated proximal RTA. This disorder presents with severe hypokalemic, hyperchloremic, metabolic acidosis, growth retardation, and ocular abnormalities including glaucoma, cataracts, and band keratopathy.</p>
        <p>Autosomal dominant: The molecular basis for this form of familial proximal RTA is unclear, and is not due to a defect in genes that are known to be involved in proximal bicarbonate reabsorption. Clinical manifestations were limited to short stature and metabolic acidosis as reported in some families.</p>
        <p>
<bold>Type 3 Mixed</bold>
</p>
        <p>Type 3 is a vanishingly rare combination of types 1 and 2. Inherited type 3 RTA is caused by mutations of CA II (chromosome 8q22) resulting in carbonic anhydrase II deficiency.</p>
        <p>
<bold>TYPE 4 Hyperkalemic</bold>
</p>
        <p>The principal buffers in the urine are ammonia and phosphate (titratable acid). Ammonium excretion requires the renal synthesis of ammonia and the secretion of hydrogen ions from the collecting tubular cells into the tubular lumen where they are trapped as ammonium (NH4+).</p>
        <p>Hypoaldosteronism causes hyperkalemia and metabolic acidosis. Hyperkalemia impairs ammonia genesis in the proximal tubule and reduces the availability of NH3 to buffer urinary hydrogen ions and decreases hydrogen ion excretion in urine. The ability to acidify urine in this type of&#x000a0;RTA is due to the inadequate amount rather than the complete absence of NH3 available for buffering of protons. Even if only a few protons are secreted distally, urine pH will fall, and this is why these patients have a urine pH less than 5.5. Most common cause of type 4 RTA in adults is hyporeninemic hypoaldosteronism which is frequently observed among patients with mild to moderate chronic kidney disease, especially if due to diabetic nephropathy.</p>
        <p>Resistance to the action of aldosterone is observed in patients with a chronic tubulointerstitial disease, those treated with potassium-sparing diuretics, and rare congenital disorder called pseudohypoaldosteronism.&#x000a0;<xref ref-type="bibr" rid="article-28371.r10">[10]</xref></p>
      </sec>
      <sec id="article-28371.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>Type 1 Distal</bold>
</p>
        <p>This type presents with Rickets, growth failure, osteomalacia due to metabolic acidosis. Hypercalciuria, hypocitraturia (citrate is reabsorbed as a buffer for hydrogen ions), and alkaline urine all leading to nephrocalcinosis (calcium phosphate stones) and recurrent UTIs; ESRF may result due to nephrocalcinosis. Hypokalemia can lead to muscle weakness and arrhythmia&#x000a0;<xref ref-type="bibr" rid="article-28371.r11">[11]</xref>.</p>
        <p>
<bold>Type 2 Proximal</bold>
</p>
        <p>Chronic metabolic acidosis leeches calcium out of bones and causes osteomalacia. Hypokalemia as potassium binds to HCO3 in urine and loss of phosphate in urine leads to hypophosphatemic rickets. There is also the loss of glucose, urate, and amino acids in the urine.</p>
        <p>
<bold>Type 3 Mixed</bold>
</p>
        <p>Characterized by a clinical syndrome known as Guibaud-Vainsel syndrome or marble brain disease, with osteopetrosis, RTA of mixed type, cerebral calcification, and mental retardation. Other clinical features include bone fractures (due to increased bone fragility) and growth failure. Excessive facial bone growth leads to facial dysmorphism and conductive hearing loss and blindness due to nerve compression.</p>
        <p>
<bold>Type 4 Hyperkalemic</bold>
</p>
        <p>It differs from other RTAs as causing hyperkalemia due to aldosterone deficiency. Mild metabolic acidosis is present.</p>
      </sec>
      <sec id="article-28371.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Clinicians should consider the presence of&#x000a0;RTA in any patient with an otherwise unexplained normal anion gap (hyperchloremic) metabolic acidosis. The first step in the diagnosis of a patient with a reduced serum bicarbonate and elevated chloride concentration is to confirm that metabolic acidosis is present by measuring the blood pH&#x000a0;<xref ref-type="bibr" rid="article-28371.r12">[12]</xref><xref ref-type="bibr" rid="article-28371.r13">[13]</xref>.</p>
        <p>
<italic toggle="yes">Plasma HCO3 Levels:</italic>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Type 1: Less than 10 to 20 mEq/L</p>
          </list-item>
          <list-item>
            <p>Type 2: 12 to 18 mEq/L</p>
          </list-item>
          <list-item>
            <p>Type 4: Greater than 17 mEq/L</p>
          </list-item>
        </list>
        <p><italic toggle="yes">Plasma Potassium:</italic> Low in type 1 and type 2, high in type 4, type 1 (due to decreased reabsorption of Na in distal tubule)&#x000a0;<xref ref-type="bibr" rid="article-28371.r14">[14]</xref></p>
        <p><italic toggle="yes">BUN/Cr:</italic>&#x000a0;Normal or near normal (rules out renal failure as the cause of acidosis)</p>
        <p><italic toggle="yes">Urinalysis:</italic> Urine pH inappropriately alkaline (greater than 5.5) despite metabolic acidosis in type 1, also in type 2 if HCO3 above reabsorptive threshold (12 to 18 mEq/L), and acidic less than 5.5 in type 2 and 4</p>
        <p><italic toggle="yes">Urine culture:</italic> Rule out urinary tract infection with the urea-splitting organism as it may elevate urine pH</p>
        <p><italic toggle="yes">Urine anion gap ([Na&#x000a0;+ K] - Cl):</italic>&#x000a0;Positive gap signifies low NH4Cl excretion which causes decrease chloride in urine along with hyperchloremic metabolic acidosis suggesting RTA.</p>
        <p>
<bold>
<italic toggle="yes">Specific tests:</italic>
</bold>
</p>
        <p><italic toggle="yes">Acid load test:</italic> Infuse acid into blood with 100 mg/kg of ammonium chloride and check urine pH hourly and plasma HCO3 at 3-hour interval. A healthy person will be able to&#x000a0;excrete acid and will decrease urine pH. Those with distal RTA cannot excrete acid and urine pH will remain basic despite increasingly acidic serum. Plasma HCO3 should drop below 21 mmol/l unless the patient vomits (in which case test should be repeated with antiemetic). If urine pH remains greater than 5.5&#x000a0;despite plasma HCO3 of 21 mmol/L the diagnosis of type 1 RTA is confirmed.</p>
        <p><italic toggle="yes">Bicarbonate infusion test:</italic> Fractional bicarbonate excretion is measured&#x000a0;after an infusion of bicarbonate. The serum bicarbonate concentration approaches the normal level in the body after the infusion, which is more than the reabsorption threshold of the patient with type 2 Proximal RTA. Urine pH rises because&#x000a0;of the appearance of greater than 15% of filtered bicarbonate in urine.</p>
        <p><italic toggle="yes">Urine Na:</italic> Type 4 RTA presents&#x000a0;with persistently high urine Na despite restricted Na diet because of aldosterone deficiency or resistance.</p>
      </sec>
      <sec id="article-28371.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Correction of chronic academia with alkali administration is warranted to prevent its catabolic effects on bone and muscles. Correction of metabolic acidosis requires Oral bicarbonate replacement at 1-2 meq/kg per day by sodium bicarbonate or potassium citrate&#x000a0;<xref ref-type="bibr" rid="article-28371.r15">[15]</xref>. Potassium citrate replacement may be necessary for patients with hypokalemia, nephrolithiasis, or nephrocalcinosis. Underlying conditions should be sought and treated. Most of the bicarbonate is absorbed in the proximal tubule, so distal RTA is relatively easy to correct. Proximal tubule will absorb the given&#x000a0;bicarbonate and correct acidosis.</p>
        <p>High doses of bicarbonate greater than 10 mmol/kg per day are required to treat type 2 RTA. Raising the serum bicarbonate concentration will increase the filtered bicarbonate load above the proximal tubule's reduced absorptive capacity, resulting in a marked bicarbonate diuresis, so a larger amount of alkali is required to account for these urine loses. Increased bicarbonate concentration in urine induced by alkali therapy also increases urinary potassium losses because increased sodium and water delivery to the distal tubule stimulates potassium secretion. Administration of potassium salts minimizes the degree of&#x000a0;hypokalemia associated with alkali therapy. Thiazide diuretics cause volume depletion which will enhance bicarbonate reabsorption in type 2 RTA.</p>
        <p>Hypophosphatemia due to decreased proximal phosphate reabsorption and reduced activation of vitamin D also occurs in some patients and may be a major contributor to the development of bone disease. Thus, both phosphate and vitamin D supplementation may be required to normalize the serum phosphate and reverse the metabolic bone disease.</p>
        <p>Fludrocortisone 0.1 mg per day is effective in managing hyperkalemia associated with aldosterone deficiency. However, it is not usually used because hypertension, heart failure, and edema may be exacerbated in patients with renal insufficiency. Most patients can be effectively managed with a limitation of dietary potassium to 40 to 60 mEq per day and, if necessary, diuretics, for example, loop or thiazide&#x000a0;<xref ref-type="bibr" rid="article-28371.r16">[16]</xref>.</p>
      </sec>
      <sec id="article-28371.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Cystinosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ehlers-Danos Syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Multiple Myeloma&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pseudohypoaldosteronism</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Pyruvate Carboxylase deficiency&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sjorgren Syndrome</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Systemic Lupus Erythematosus&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Tyrosinemia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Wilson disease&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28371.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>In patients with a non-anion gap metabolic acidosis, the following factors should be considered before labeling the diagnosis of RTA:</p>
        <list list-type="bullet">
          <list-item>
            <p>As urea is converted to ammonia (NH3) and bicarbonate (HCO3) by urease-positive organisms, urinary tract infections by these organisms can cause a misleading increase in urine pH so a urinalysis&#x000a0;and urine culture should be performed before diagnosing RTA, if indicated.</p>
          </list-item>
          <list-item>
            <p>Severe volume depletion which causes an increase in sodium reabsorption in the proximal tubule and decreased&#x000a0;Na delivery to distal tubule also causes reduced proton secretion, raising the pH of urine.&#x000a0;Thus, urine Na concentration should be greater than 25 meq/L for diagnosing RTA.</p>
          </list-item>
        </list>
        <p>Incomplete distal RTA should be considered in any calcium stone formers with a urine pH persistently 5.5 or higher in the absence of urinary&#x000a0;tract infection and normal or near normal serum HCO3 concentration.</p>
        <p>The most common cause of type&#x000a0;2 proximal RTA in adults is monoclonal gammopathy which should be excluded in all adults with proximal RTA unless another cause is found.</p>
        <p>Patients with proximal RTA should also be evaluated for Fanconi syndrome with serum and urine measurements looking for renal glycosuria, hypophosphatemia, and hypouricemia.</p>
      </sec>
      <sec id="article-28371.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Kidneys play a pivotal role in maintaining the acid-base balance of body along with lungs, and they do so by reabsorbing filtered bicarbonate and removing excess hydrogen ions. Renal disorders due to the removal of HCO3 or acid handling in the presence of relatively preserved GFR are collectively referred to as renal tubular acidosis. It is a non-anion gap hyperchloremic metabolic acidosis.</p>
        <p>There are four subtypes of RTA. The three main subtypes of RTA correlate with three mechanisms that facilitate renal acid-base handling, i.e., proximal bicarbonate reabsorption mainly as a result of Na-H exchange (85% to 90%), distal hydrogen ion excretion-primarily a function of collecting tubules and generation of NH3, the principal urinary buffer. Because there are many causes of RTA, these disorders should be managed by an interprofessional team that includes a nephrologist, internist, rheumatologist, and hematologist. The treatment depends on the cause but in those with a reversible cause, the prognosis is good.</p>
      </sec>
      <sec id="article-28371.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28371&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28371">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/kidney-health/renal-tubular-acidosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28371">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28371/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28371">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28371.s13">
        <title>References</title>
        <ref id="article-28371.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roth</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Renal tubular acidosis: a new look at an old problem.</article-title>
            <source>Clin Pediatr (Phila)</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>40</volume>
            <issue>10</issue>
            <fpage>533</fpage>
            <page-range>533-43</page-range>
            <pub-id pub-id-type="pmid">11681819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiner</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>[Renal Involvement in Connective Tissue Diseases].</article-title>
            <source>Dtsch Med Wochenschr</source>
            <year>2018</year>
            <month>Jan</month>
            <volume>143</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-100</page-range>
            <pub-id pub-id-type="pmid">29359289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dharmarajan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ammar</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Expanding the differential: toluene-induced toxicity.</article-title>
            <source>BMJ Case Rep</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>2017</volume>
            <pub-id pub-id-type="pmid">28765189</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Emmett</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fenves</surname>
                <given-names>AZ</given-names>
              </name>
            </person-group>
            <article-title>Topiramate and metabolic acidosis: an evolving story.</article-title>
            <source>Hosp Pract (1995)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>192</fpage>
            <page-range>192-195</page-range>
            <pub-id pub-id-type="pmid">28828886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bello</surname>
                <given-names>CHPRT</given-names>
              </name>
              <name>
                <surname>Duarte</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Vasconcelos</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Diabetes mellitus and hyperkalemic renal tubular acidosis: case reports and literature review.</article-title>
            <source>J Bras Nefrol</source>
            <year>2017</year>
            <season>Oct-Dec</season>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>481</fpage>
            <page-range>481-485</page-range>
            <pub-id pub-id-type="pmid">29319780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koratala</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ruchi</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Hypokalemia: A potentially life-threatening complication of tenofovir therapy.</article-title>
            <source>SAGE Open Med Case Rep</source>
            <year>2017</year>
            <volume>5</volume>
            <fpage>2050313X17741010</fpage>
            <pub-id pub-id-type="pmid">29163953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trepiccione</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Prosperi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>de la Motte</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>H&#x000fc;bner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Chambrey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eladari</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Capasso</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>New Findings on the Pathogenesis of Distal Renal Tubular Acidosis.</article-title>
            <source>Kidney Dis (Basel)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>98</fpage>
            <page-range>98-105</page-range>
            <pub-id pub-id-type="pmid">29344504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fearn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Allison</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Halbritter</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bourgeois</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pastor-Arroyo</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Hildebrandt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tasic</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hernando</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sayer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Werner</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Clinical, biochemical, and pathophysiological analysis of SLC34A1 mutations.</article-title>
            <source>Physiol Rep</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>12</issue>
            <fpage>e13715</fpage>
            <pub-id pub-id-type="pmid">29924459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Myers</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Yuan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Felmlee</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Pei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Xing</surname>
                <given-names>XP</given-names>
              </name>
              <name>
                <surname>Marshall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Parker</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>A novel mutant Na<sup>+</sup> /HCO3<sup>-</sup> cotransporter NBCe1 in a case of compound-heterozygous inheritance of proximal renal tubular acidosis.</article-title>
            <source>J Physiol</source>
            <year>2016</year>
            <month>Nov</month>
            <day>01</day>
            <volume>594</volume>
            <issue>21</issue>
            <fpage>6267</fpage>
            <page-range>6267-6286</page-range>
            <pub-id pub-id-type="pmid">27338124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karet</surname>
                <given-names>FE</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms in hyperkalemic renal tubular acidosis.</article-title>
            <source>J Am Soc Nephrol</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>2</issue>
            <fpage>251</fpage>
            <page-range>251-4</page-range>
            <pub-id pub-id-type="pmid">19193780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarma</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Hypokalemic Paralysis Due to Primary Sjogren Syndrome.</article-title>
            <source>Indian J Endocrinol Metab</source>
            <year>2018</year>
            <season>Mar-Apr</season>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>287</fpage>
            <page-range>287-289</page-range>
            <pub-id pub-id-type="pmid">29911048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohebbi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Pathophysiology, diagnosis and treatment of inherited distal renal tubular acidosis.</article-title>
            <source>J Nephrol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>511</fpage>
            <page-range>511-522</page-range>
            <pub-id pub-id-type="pmid">28994037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berend</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Review of the Diagnostic Evaluation of Normal Anion Gap Metabolic Acidosis.</article-title>
            <source>Kidney Dis (Basel)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>149</fpage>
            <page-range>149-159</page-range>
            <pub-id pub-id-type="pmid">29344509</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yaxley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pirrone</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Review of the Diagnostic Evaluation of Renal Tubular Acidosis.</article-title>
            <source>Ochsner J</source>
            <year>2016</year>
            <season>Winter</season>
            <volume>16</volume>
            <issue>4</issue>
            <fpage>525</fpage>
            <page-range>525-530</page-range>
            <pub-id pub-id-type="pmid">27999512</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marangella</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Use of citrate in patients with nephrolithiasis].</article-title>
            <source>G Ital Nefrol</source>
            <year>2017</year>
            <month>Aug</month>
            <day>01</day>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>51</fpage>
            <page-range>51-60</page-range>
            <pub-id pub-id-type="pmid">28762682</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28371.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dobbin</surname>
                <given-names>SJH</given-names>
              </name>
              <name>
                <surname>Petrie</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lean</surname>
                <given-names>MEJ</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Fludrocortisone therapy for persistent hyperkalaemia.</article-title>
            <source>Diabet Med</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>34</volume>
            <issue>7</issue>
            <fpage>1005</fpage>
            <page-range>1005-1008</page-range>
            <pub-id pub-id-type="pmid">28375568</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
